Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/008586COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS
WO 13.01.2022
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
Appl.No PCT/EP2021/068800 Applicant GRIFOLS WORLDWIDE OPERATIONS LIMITED Inventor BARNETT, Thomas
Disclosed herein are pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.
2.WO/2022/008976USE OF GDF11 TO DIAGNOSE AND TREAT ANXIETY AND DEPRESSION
WO 13.01.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/IB2021/000495 Applicant INSTITUT PASTEUR Inventor KATSIMPARDI, Lida
Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.
3.WO/2022/009081DRUG FOR USE AGAINST THE NOVEL CORONAVIRUS DISEASE, COVID-19
WO 13.01.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IB2021/056031 Applicant TORVALD RANTA FORETAGSJURIDIK AB Inventor KHANYKOV, Alexandr Vladimirovich
The invention concerns a medicinal drug effective for the treatment of COVID-19 disease caused by the SARS-Cov-2 virus and preventing the development of its dangerous complications associated with pulmonary edema. For this purpose, a drug is proposed comprising aprotinin as a pharmaceutically active component in the form of a dry powder aerosol with a particle size of less than 1.0 μm. Such a drug provides the possibility of targeted delivery of aprotinin to the lower respiratory tract and alveoli, which makes it possible to influence both the etiology (due to the antiviral effect of aprotinin) and the pathogenesis of COVID-19 disease (due to the anti-inflammatory effect of aprotinin) directly in the focus of the pathologic pathway.
4.WO/2022/011151MYBPC3 POLYPEPTIDES AND USES THEREOF
WO 13.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2021/040906 Applicant CHILDREN'S MEDICAL CENTER CORPORATION Inventor PU, William, T.
Provided herein are compositions and methods for treating a disorder associated with abnormal RYR2 function (e.g., arrhythmia or heart failure). In some embodiments, method comprises administering to a subject in need thereof an effective amount of a polypeptide comprising a C -terminal domain of Cardiac Myosin binding protein C (MYBPC3) or a nucleic acid or an rAAV encoding such polypeptide.
5.WO/2022/011256FUSION CONSTRUCTS AND METHODS OF USING THEREOF
WO 13.01.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2021/041082 Applicant PRECIGEN, INC. Inventor SABZEVARI, Helen
A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
6.20220008387METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANE
US 13.01.2022
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
Appl.No 17303353 Applicant Boulder BioScience LLC Inventor Michael A. Zeligs

Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.

7.WO/2022/008902METHOD FOR TREATING A GD2-POSITIVE CANCER
WO 13.01.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/GB2021/051721 Applicant EUSA PHARMA (UK) LIMITED Inventor LODE, Holger Nikolaus
A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.
8.20220008365Treating Intraocular Retinoblastoma with Inhibitors of Histone Modification
US 13.01.2022
Int.Class A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
Appl.No 17294339 Applicant Vanderbilt University Inventor Anthony B. Daniels

Methods of treating a proliferative conditions of the eye, comprising administering to a patient a therapeutically effective amount of a composition that comprises a compound that inhibits the biological activity of a mammalian histone deacetylase (HDAC), or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.

9.20220008507METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION AND ASSOCIATED COAGULOPATHY
US 13.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 17487099 Applicant UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ Inventor Wolfram RUF

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

10.20220009998ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
US 13.01.2022
Int.Class C07K 14/71
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
71for growth factors; for growth regulators
Appl.No 17460578 Applicant Regeneron Pharmaceuticals, Inc. Inventor Shunhai Wang

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.